2. Search Result
Search Result
Results for "

phagocytosis

" in MedChemExpress (MCE) Product Catalog:

55

Inhibitors & Agonists

3

Fluorescent Dye

2

Biochemical Assay Reagents

6

Peptides

13

Inhibitory Antibodies

5

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-154921
    Lactosylceramide (bovine buttermilk)

    LacCer (bovine buttermilk)

    		 Reactive Oxygen Species Inflammation/Immunology
    Lactosylceramide (bovine buttermilk) (LacCer (bovine buttermilk)) is a sphingolipid that highly expressed on the plasma membranes of human phagocytes. Lactosylceramide mediates phagocytosis, chemotaxis, and superoxide generation .
    Lactosylceramide (bovine buttermilk)
  • HY-P99706
    Ligufalimab

    AK 117

    		 CD47 Interleukin Related Cancer
    Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
    Ligufalimab
  • HY-157131
    TRPV2-selective blocker 1

    		TRP Channel Neurological Disease
    TRPV2-selective blocker 1 (compound IV2-1) is a selective TRPV2 channel blocker with an IC50 of 6.3 μM. TRPV2-selective blocker 1 does not affect TRPV1, TRPV3 or TRPV4 channels. TRPV2-selective blocker 1 also inhibits TRPV2-mediated Ca 2+ influx in macrophages, and inhibits macrophage phagocytosis .
    TRPV2-selective blocker 1
  • HY-P99273
    Vorsetuzumab

    		TNF Receptor Cancer
    Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma .
    Vorsetuzumab
  • HY-152246
    ZIM

    		DNA/RNA Synthesis Cancer
    ZIM, a norbornene derived from 4-Aminoantipyrine, is a potent inducer of DNA damage, causing genomic and chromosomal damage as well as inducing cell death and activating phagocytosis. ZIM has chemotherapeutic potential for use in cancer research .
    ZIM
  • HY-P99777
    Ontorpacept

    TTI-621

    		 CD47 Cancer
    Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
    Ontorpacept
  • HY-P0064
    Palmitoyl Tetrapeptide-3

    Palmitoyl Tetrapeptide-7

    		 Interleukin Related Inflammation/Immunology
    Palmitoyl Tetrapeptide-3 (Palmitoyl Tetrapeptide-7) is a synthetic peptide corresponding to amino acids 341-344 of the human immunoglobulin heavy chain, with the ability to stimulate phagocytosis. Palmitoyl tetrapeptide-3 reduces interleukin-6 (IL-6) secretion in keratinocytes and inhibits the UVB radiation-exposure inflammatory response of skin. Palmitoyl tetrapeptide-3 It also has anti-inflammatory and anti-aging effects, reducing skin wrinkles by promoting the production of elastic fibers in the papillary dermis .
    Palmitoyl Tetrapeptide-3
  • HY-115983
    DMUP

    		CD47 Apoptosis Cancer
    DMUP is a potent CD47-SIRPα axis inhibitor. DMUP induces apoptosis and increases the macrophage phagocytosis in A549 cells. DMUP decreases the expression of CD47 and SIRPα protein. DMUP shows antitumor activity .
    DMUP
  • HY-156996
    AGI-134

    		Others Inflammation/Immunology Cancer
    AGI-134 is a fully synthetic alpha-Gal glycolipid. AGI-134 invokes CD8+ T cell-mediated immunity. AGI-134 induces tumor cell destruction and phagocytosis .
    AGI-134
  • HY-169089
    RP-182-PEG3-K(palmitic acid)

    		Others Cancer
    RP-182-PEG3-K palmitic acid (Compound 1a) inhibits CD206 high M2-like macrophage (IC50 of 3.2 µM) and induces phagocytosis. RP-182-PEG3-K palmitic acid exhibits antitumor efficacy in mouse B16 melanoma allografts .
    RP-182-PEG3-K(palmitic acid)
  • HY-P10707
    Tpp-CAQK

    		Endogenous Metabolite Inflammation/Immunology
    Tpp-CAQK can bind to mitochondria, enabling the construction of an engineered mitochondrial compound, Mito-Tpp-CAQK, with excellent bioactivity. Mito-Tpp-CAQK can be internalized by macrophages, thereby enhancing the phagocytosis of myelin debris, alleviating mitochondrial dysfunction, and reducing proinflammatory profiles, ultimately facilitating tissue repair and functional recovery in mice after spinal cord injury .
    Tpp-CAQK
  • HY-P10707A
    Tpp-CAQK TFA

    		Endogenous Metabolite Inflammation/Immunology
    Tpp-CAQK TAF can bind to mitochondria, enabling the construction of an engineered mitochondrial compound, Mito-Tpp-CAQK TFA, with excellent bioactivity. Mito-Tpp-CAQK TFA can be internalized by macrophages, thereby enhancing the phagocytosis of myelin debris, alleviating mitochondrial dysfunction, and reducing proinflammatory profiles, ultimately facilitating tissue repair and functional recovery in mice after spinal cord injury .
    Tpp-CAQK TFA
  • HY-A0183
    Phosphatidylserine

    Phospholipids, phosphatidylserines; Serine glycerophosphatides

    		 Akt TGF-β Receptor Inflammation/Immunology
    Phosphatidylserine (Phospholipids) is a well-conserved anti-inflammatory and immunosuppressive signal. Phosphatidylserine is involved in membrane translocation and the activation of protein kinase C, participating in Akt signaling through its interaction with PIP3. The local exposure of Phosphatidylserine can interact with complement and other proteins, promoting microglial phagocytosis during critical periods of synaptic refinement. Phosphatidylserine can promote blood coagulation in the extracellular environment and acts as a "eat me" signal to clear out apoptotic cells. Phosphatidylserine can suppress inflammation in tissues by inducing TGF-β secretion and inhibiting immune responses .
    Phosphatidylserine
  • HY-P99381
    XmAb 5592
    1 Publications Verification

    		 Transmembrane Glycoprotein Cancer
    XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .
    XmAb 5592
  • HY-D1671
    TRITC-DHPE

    		Fluorescent Dye Others
    TRITC-DHPE is a rhodamine-labeled glycerophosphate ethanolamine lipid, with head groups marked with bright red fluorescent TRITC dye (λEx/λEm=514/580 nm). TRITC-DHPE can be used for membrane fusion assay to trace lipid processing in intracellular phagocytosis. TRITC-DHPE can serves as an energy transfer receptor for NBD, BODIPY and fluorescein lipid probes .
    TRITC-DHPE
  • HY-NP006
    Protein A

    SPA

    		 Endogenous Metabolite Inflammation/Immunology
    Protein A (SPA) is an immunoglobulin (Ig) binding protein that exists on the surface of bacteria and can be freely secreted into the extracellular environment. Protein A blocks opsonization and phagocytosis and induces B-cell death in vitro by binding to the Fc region of antibodies and the Fab region of B-cell receptors. Protein A has the ability to inhibit opsonization and phagocytosis in vitro .
    Protein A
  • HY-103348
    Boc-Asp(OMe)-fluoromethyl ketone

    Boc-Asp(OMe)-FMK

    		 Caspase Inflammation/Immunology
    Boc-Asp(OME)-Fluoromethyl Ketone is a broad range caspase inhibitor that inhibits Fas-mediated phagocytosis and oxidative rupture inhibition, but does not affect the chemotactic activity of IL-8 .
    Boc-Asp(OMe)-fluoromethyl ketone
  • HY-164290
    Rhodady C10

    		Dynamin Infection Neurological Disease
    Rhodady C10 (Compound C10) is a dynamin I GTPase inhibitor. Rhodady C10 blocks receptor-mediated endocytosis (IC50: 7 μM). Dynamin is involved in clathrin-independent endocytosis, phagocytosis, and caveolae internalization .
    Rhodady C10
  • HY-15130
    DL-O-Phosphoserine

    		Endogenous Metabolite Metabolic Disease
    DL-O-Phosphoserine is a normal metabolite in human biofluids and is a mixture of phosphoserine with two stereochemical structures (D-type and L-type O-phospho-serine). O-phospho-L-serine is a competitive inhibitor of serine racemase and phagocytosis. O-phospho-L-serine inhibits the enzymatic reaction by competing with the active site of serine racemase, thereby affecting the production of D-serine. O-phospho-L-serine also mimics the phosphatidylserine head group, binds to the phosphatidylserine receptor, interferes with phagocytic signal transduction, and partially blocks the phagocytosis of apoptotic cells by cells. O-phospho-L-serin can be used in the research of retinal regeneration, bone repair, and insect growth and development .
    DL-O-Phosphoserine
  • HY-106350
    Cefpimizole

    U-63196E; AC-1370

    		 Antibiotic Bacterial Infection Inflammation/Immunology
    Cefpimizole (U-63196E) is a broad-spectrum cephalosporin antibiotic. Cefpimizole inhibits many Ampicillin (HY-B0522)-resistant bacteria, and is active against gram-negative species. Cefpimizole augments phagocytosis of macrophages and neutrophils .
    Cefpimizole
  • HY-P990707
    Maplirpacept

    TTI-622; PF-07901801

    		 CD47 Inflammation/Immunology
    Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47 .
    Maplirpacept
  • HY-106350A
    Cefpimizole sodium

    U-63196E sodium; AC-1370 sodium

    		 Antibiotic Bacterial Infection Inflammation/Immunology
    Cefpimizole (U-63196E) sodium is a broad-spectrum cephalosporin antibiotic. Cefpimizole sodium inhibits many Ampicillin (HY-B0522)-resistant bacteria, and is active against gram-negative species. Cefpimizole sodium augments phagocytosis of macrophages and neutrophils .
    Cefpimizole sodium
  • HY-122008
    ORM-3819

    		Bacterial Infection
    Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) arginine is a broad-spectrum antistaphylococcal agent. Levonadifloxacin arginine has antimicrobial activity against methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus and reduces phagocytosis of MRSA and MSSA strains by monocytic THP-1.
    ORM-3819
  • HY-14926B
    Levonadifloxacin arginine

    (S)-(-)-Nadifloxacin arginine; WCK 771 arginine

    		 Bacterial Infection
    Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) arginine is a broad-spectrum antistaphylococcal agent. Levonadifloxacin arginine has antimicrobial activity against methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus and reduces phagocytosis of MRSA and MSSA strains by monocytic THP-1 cells .
    Levonadifloxacin arginine
  • HY-126346
    DL-175

    		GPR84 Inflammation/Immunology
    DL-175 (compound 13) is a selective GPR84 agonist with biased agonistic activity. DL-175 can selectively activate functional responses in immune cells and induce enhanced chemotaxis and phagocytosis of human bone marrow cells. DL-175 is a potential chemical probe .
    DL-175
  • HY-P99015
    Dacetuzumab

    		TNF Receptor Cancer
    Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .
    Dacetuzumab
  • HY-170506
    KB-208

    		Others Inflammation/Immunology
    KB-208 is a phagocytosis inhibitor that improves immune thrombocytopenia (ITP) in mouse models at a dose of 1 mg/kg. KB-208 does not affect other blood parameters and does not elevate serum toxicity biomarkers. KB-208 can be used in immunology research .
    KB-208
  • HY-106835
    Flobufen

    VUFB 16066

    		 COX Lipoxygenase Inflammation/Immunology
    Flobufen (VUFB 16066) is a non-steroidal anti-inflammatory agent and cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) inhibitor agent. Flobufen inhibits alloantigen-driven cellular immune responses and stimulates phagocytosis of peritoneal cells. Flobufen can improve immunopathological disorders and has an inhibitory effect on rheumatoid arthritis .
    Flobufen
  • HY-P99029
    Magrolimab
    2 Publications Verification

    Hu5F9-G4

    		 CD47 Cancer
    Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer .
    Magrolimab
  • HY-P9976A
    Isatuximab (anti-CD38)
    1 Publications Verification

    		 CD38 Cancer
    Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) .
    Isatuximab (anti-CD38)
  • HY-168091
    YM-I-26

    		NOD-like Receptor (NLR) Interleukin Related Inflammation/Immunology
    YM-I-26 is a selective NLRP3 inflammasome inhibitor. YM-I-26 enhances the phagocytosis of β-amyloid protein by mouse microglial BV2 cells and inhibits the production of IL-1β and IL-10. YM-I-26 can be used to study the immunomodulatory activity associated with inflammation .
    YM-I-26
  • HY-125527
    Resolvin D1

    RvD1

    		 Endogenous Metabolite Inflammation/Immunology
    Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α–mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages .
    Resolvin D1
  • HY-P10091
    CD24/Siglec-10 blocking peptide, CSBP

    		PD-1/PD-L1 Cancer
    CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP can induce the phagocytosis of tumor cell .
    CD24/Siglec-10 blocking peptide, CSBP
  • HY-131180
    BMS-986235
    1 Publications Verification

    LAR-1219

    		 Formyl Peptide Receptor (FPR) Cardiovascular Disease
    BMS-986235 (LAR-1219) is a selective, orally active formyl peptide receptor 2 (FPR2) agonist, with EC50s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 has potential for the prevention of heart failure .
    BMS-986235
  • HY-W094758A
    4-Di-1-ASP

    		Fluorescent Dye Cancer
    4-Di-1-ASP is a styryl dye used to stain glioma cells in living brain tissue for analysis of cell structure, viability, proliferation and endocytosis, cytokinesis and phagocytosis, as well as for observation of mitochondrial structures in living cells. 4-Di-1-ASP fluoresces green when imaged microscopically (λex /λem = 475/606 nm) .
    4-Di-1-ASP
  • HY-B0019
    Azasetron

    (Rac)-SENS-401 free base

    		 5-HT Receptor Neurological Disease
    Azasetron ((Rac)-SENS-401 free base) is an antiemetic drug with 5-HT3 receptor antagonist activity. Azasetron is often used as a preventive measure for postoperative nausea and vomiting or chemotherapy-induced nausea and vomiting. Azasetron does not impair neutrophil chemotaxis or phagocytosis and does not scavenge O(-)(2) or H(2)O(2) generated by cell-free systems .
    Azasetron
  • HY-113533
    Resolvin D4

    RvD4

    		 Bacterial Inflammation/Immunology
    Resolvin D4 (RvD4), a specialized proresolving mediator, can be produced in bioactive levels during S. aureus infection .
    Resolvin D4
  • HY-167715
    Traxanox

    		Histamine Receptor Phosphodiesterase (PDE) Inflammation/Immunology
    Traxanox is an orally available diuretic that enhances phagocytosis of yeast granules by mouse peritoneal macrophages and rat peritoneal polymorphonuclear leukocytes in vitro. Traxanox inhibits IgE-mediated histamine release and cyclic AMP phosphodiesterase activity.Traxanox exhibits anti-inflammatory activity, as it inhibits the anaphylactoid reaction and reduces pleural fluid accumulation in experimental models of inflammation. Traxanox also demonstrates a synergistic effect when combined with hydrocortisone or indomethacin in suppressing adjuvant arthritis in rats.
    Traxanox
  • HY-P9983
    Lintuzumab

    SGN-33; HuM-195

    		 Transmembrane Glycoprotein Radionuclide-Drug Conjugates (RDCs) Inflammation/Immunology
    Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .
    Lintuzumab
  • HY-125527S
    Resolvin D1-d5

    RvD1-d5

    		 Isotope-Labeled Compounds Endogenous Metabolite Inflammation/Immunology
    Resolvin D1-d5 is the deuterium labeled Resolvin D1. Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α-mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages .
    Resolvin D1-d5
  • HY-P9976
    Isatuximab
    1 Publications Verification

    		 Apoptosis Cancer
    Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .
    Isatuximab
  • HY-N6727
    Gliotoxin

    Aspergillin

    		 Apoptosis PKA NF-κB Bacterial Fungal Antibiotic Infection Inflammation/Immunology Cancer
    Gliotoxin is a secondary metabolite, the most abundant mycotoxin secreted by A. fumigatus, inhibits the phagocytosis of macrophages and the immune functions of other immune cells . Gliotoxin inhibits inducible NF-κB activity by preventing IκB degradation, which consequently induces host-cell apoptosis . Gliotoxin activates PKA and increases intracellular cAMP concentration; modulates actin cytoskeleton rearrangement to facilitate A. fumigatus internalization into lung epithelial cells . Gliotoxin is a potent NOTCH2 transactivation inhibitor, can effectively induce apoptosis of chronic lymphocytic leukemia (CLL) cells .
    Gliotoxin
  • HY-P10420
    RS17

    		CD47 Interleukin Related Cancer
    RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape .
    RS17
  • HY-P10947
    MACTIDE-V

    		Epigenetic Reader Domain YAP Cancer
    MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 + tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .
    MACTIDE-V
  • HY-D0970
    Diphenyl Blue
    2 Publications Verification

    Direct Blue 14; Trypan Blue

    		 Fluorescent Dye Others
    Diphenyl Blue (Trypan Blue) is a cell active dye, the most commonly used dye for the identification of dead cells, of en used to test cell membrane integrity and cell viability. Diphenyl Blue staining is one of the methods for tissue and cell culture. When cells are deactivated or have incomplete cell membranes, Diphenyl Blue can stain them Blue. Normal living cells with intact cell membranes reject Diphenyl blue and do not stain them blue. However, macrophages are capable of phagocytosis of Diphenyl Blue, so it can be used as a living stain for macrophages .
    Diphenyl Blue
  • HY-162020
    SB1617

    		Tau Protein Neurological Disease Inflammation/Immunology
    SB1617 is a neuroinflammation-modulating agent, and has neuroprotective effect by reducing pathogenic tau levels through microglia-mediated anti-inflammatory activity .
    SB1617
  • HY-P99117
    Cadonilimab

    AK104

    		 PD-1/PD-L1 CTLA-4 Inflammation/Immunology Cancer
    Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .
    Cadonilimab
  • HY-B1398
    Ampyrone
    1 Publications Verification

    4-Aminophenazone

    		 COX Drug Metabolite Neurological Disease Inflammation/Immunology Cancer
    Ampyrone (4-Aminophenazone; 4-Aminoantipyrine) is a reversible and low-damage optical clearing agent and non-selective COX inhibitor based on UV absorption properties. Ampyrone can improve the optical transmittance of mouse skin and other tissues. Ampyrone can induce tissue refractive index matching by enhancing UV absorption, reduce light scattering, and achieve tissue transparency in vivo. Ampyrone reduces the synthesis of prostaglandin PGE2, thereby exerting anti-inflammatory, analgesic and antipyretic effects. Ampyrone inhibits DNA damage, cell apoptosis and immune cell phagocytosis induced by Doxorubicin (HY-15142A) and Cisplatin (HY-17394), etc., and participates in the regulation of toxicity in tumor chemotherapy .
    Ampyrone
  • HY-W015600
    2-Acetamidophenol

    Orthocetamol

    		 Ferroptosis Glutathione Peroxidase Reactive Oxygen Species LDLR Cardiovascular Disease Inflammation/Immunology
    2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe 2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .
    2-Acetamidophenol
  • HY-121365
    Forphenicinol

    		Bacterial Infection
    Forphenicinol is an immunomodulator and a derivative of the bacterial metabolite forphenicine. It increases the phagocytosis of yeast by peritoneal macrophages isolated from thioglycolate-stimulated mice. Forphenicinol (100 μg/animal) prevents cyclophosphamide-induced suppression of delayed-type hypersensitivity (DTH), as well as enhances DTH in response to the hapten oxazolone or sheep red blood cells in mice. It enhances the bactericidal activity of macrophages against P. aeruginosa in mice when administered at a dose of 0.5 mg/kg.2 Forphenicinol (15.6-1,000 μg/animal) increases survival in a mouse model of P. aeruginosa infection. It also inhibits tumor growth in S180 sarcoma and IMC carcinoma mouse xenograft models when administered at doses ranging from 0.05 to 5 mg/kg per day.
    Forphenicinol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: